Pages that link to "Q74623160"

The following pages link to Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785) (Q74623160):

Displaying 28 items.

• Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants (Q24810573) (← links)
• Induction of lateral lumens through disruption of a monoleucine-based basolateral-sorting motif in betacellulin (Q27339929) (← links)
• Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis (Q28593435) (← links)
• Epidermal growth factor receptor mutations in lung cancer (Q29615474) (← links)
• Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. (Q33801908) (← links)
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib (Q33821320) (← links)
• Chemical genetics identifies small-molecule modulators of neuritogenesis involving neuregulin-1/ErbB4 signaling (Q33863150) (← links)
• A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications (Q33900952) (← links)
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases (Q33906140) (← links)
• The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases (Q34248529) (← links)
• Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors (Q34589789) (← links)
• Targeting the function of the HER2 oncogene in human cancer therapeutics (Q34766486) (← links)
• Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma (Q35088274) (← links)
• Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas (Q36026392) (← links)
• EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer (Q37240726) (← links)
• ErbBs in lung cancer (Q37249978) (← links)
• HER-2-directed, small-molecule antagonists (Q37336019) (← links)
• The soluble protease ADAMDEC1 released from activated platelets hydrolyzes platelet membrane pro-epidermal growth factor (EGF) to active high-molecular-weight EGF. (Q38705556) (← links)
• Cellular Response to Titanium Dioxide Nanoparticles in Intestinal Epithelial Caco-2 Cells is Dependent on Endocytosis-Associated Structures and Mediated by EGFR (Q38708542) (← links)
• EGFR and myosin II inhibitors cooperate to suppress EGFR-T790M-mutant NSCLC cells (Q39390169) (← links)
• Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance (Q39960713) (← links)
• Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents (Q40702060) (← links)
• Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation (Q42173414) (← links)
• MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines (Q43621540) (← links)
• EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats (Q44609775) (← links)
• Microwave assisted synthesis of N-arylheterocyclic substituted-4-aminoquinazoline derivatives (Q46930084) (← links)
• Combinatorial chemoprevention of intestinal neoplasia (Q74268548) (← links)
• Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor (Q83143406) (← links)